Vanguard Group Inc Exelixis, Inc. Transaction History
Vanguard Group Inc
- $4.96 Trillion
- Q1 2024
A detailed history of Vanguard Group Inc transactions in Exelixis, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 30,819,783 shares of EXEL stock, worth $668 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
30,819,783
Previous 31,671,090
2.69%
Holding current value
$668 Million
Previous $760 Million
3.74%
% of portfolio
0.01%
Previous 0.02%
Shares
12 transactions
Others Institutions Holding EXEL
# of Institutions
459Shares Held
246MCall Options Held
1.7MPut Options Held
1.02M-
Black Rock Inc. New York, NY34.9MShares$757 Million0.02% of portfolio
-
Farallon Capital Management LLC San Francisco, CA26.7MShares$579 Million2.95% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny15.1MShares$328 Million0.56% of portfolio
-
State Street Corp Boston, MA13.1MShares$284 Million0.01% of portfolio
-
Jpmorgan Chase & CO New York, NY5.32MShares$115 Million0.01% of portfolio
About EXELIXIS, INC.
- Ticker EXEL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 321,832,000
- Market Cap $6.98B
- Description
- Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...